Updated terminology for gamete and embryo donors: directed (identified) to replace “known” and nonidentified to replace “anonymous”: a committee opinion

Ethics and Practice Committees of the American Society for Reproductive Medicine
American Society for Reproductive Medicine, Birmingham, Alabama

Technology and the regulatory framework in which we practice and live are continually evolving. Shifting mores and the ease with which individuals can identify one another with the assistance of social media and deoxyribonucleic acid (DNA) testing has necessitated the current change in medical terminology. For decades, gamete and embryo donors were referred to as “known” if they had a relationship with the intended parent(s) and “anonymous” if they were unknown to one another at the time of the donation. The American Society for Reproductive Medicine encourages all stakeholders with an interest in gamete and embryo donation to adopt directed (identified) in lieu of “known” and nonidentified in lieu of “anonymous” to more accurately describe the relationships between donors and recipients in this new era of social media and genetic information sharing. (Fertil Steril 2022;–:––:–. ©2022 by American Society for Reproductive Medicine.)

Key Words: Sperm donation, oocyte donation, gamete donation, assisted reproduction

DIALOG: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/34835
As such, the American Society for Reproductive Medicine has changed the nomenclature of gamete and embryo donation. Donors who were previously described as known will now be referred to as directed (identified) donors, and those previously described as anonymous will be referred to as non-identified donors.

**DIRECTED DONORS**

The choice of the term directed (identified) donor, previously called known donor, was selected to align with the Food and Drug Administration (FDA) regulations (4). The gametes from a directed (identified) donor who is deemed “ineligible” based on FDA guidance for tissue donation may in some cases be used if both parties are aware of the theoretical infectious or genetic risks to the recipient(s) and offspring and consent to move forward with the donation (5). The categorization of an individual as a directed (identified) donor affords recipients the option of waiving some exclusion criteria when they value the benefits of the known donor (e.g., sister to sister egg donation) so strongly that they are willing to accept the presumably low risk of infectious disease transmission. The use of the term directed (identified) mirrors the FDA language that specifies exclusions and exceptions for gamete and embryo donation based on whether the parties are known to one another. The new terminology should assist physicians and administrators as they interpret and apply the FDA regulations to clinical practice.

**NONIDENTIFIED DONORS**

The choice of the term nonidentified for those who were previously called anonymous donors acknowledges the intention of all involved in the donation process, including donors and recipients, as well as any medical, professional, or coordinating entities or professionals, not to share identifying information of the donor or recipient with one another. The intention at the time a nonidentified donation contract is entered into, or the donation undertaken, is that the identities of the donor, recipient, and any resulting offspring will remain unknown to one another to the extent permitted under law or to an explicit and limited degree, such as when a contract or consent document may allow for arranging contact between the donor-conceived offspring and the donor upon the offspring reaching a specific age, often the age of majority. These latter types of arrangements are sometimes referred to as open-identity arrangements, and the donors who agree to them are referred to as open-identity donors.

Example of unplanned identification (Figure 1): Family A: Use of donor gamete never disclosed to child. Family B: “Anonymous” gamete donation never disclosed by the donor. Children A and B: Independently send DNA to a DTC DNA Laboratory without parental knowledge. Each is notified about a 1/2 sibling. Difficult conversations ensue.

This scenario applies equally to egg, sperm, and embryo donation. Furthermore, it need not be the donor-conceived offspring who participate; it could be other genetically related individuals. Finally, in cases of directed gamete donation, where the donor and recipient are known to one another, the parties involved will want to consider who are the other genetic relatives that should be made privy to the information, as they may inadvertently find out about the donation at some future date if they participate in genetic testing.

![FIGURE 1](image_url)

Unplanned identification. DNA = deoxyribonucleic acid; DTC = direct-to-consumer.

CONCLUSION

In conclusion, given a multitude of global social media platforms, increasingly accessible and used DTC DNA services, and facial recognition technology, true anonymity between donors and recipients can no longer be guaranteed. All parties involved in gamete and embryo donation should be aware that identities may be discovered by the resulting offspring and other genetically linked individuals at any future time. This holds for both directed (identified) and nonidentified donations. Complicating matters is the fact that past donors, whether they donated with the intention of anonymity or not, are now potentially discoverable at any future date. The extent to which such revelations will occur is unknown.

A 2019 estimate suggested that approximately 8% of the US population had already sent DNA to a DTC DNA vendor with speculation that the number could more than triple over the next several years, thus greatly expanding the population of people who can identify one another based on their genetic links (6). A related, but somewhat different, scenario is the active pursuit of connection among offspring who know they were conceived from donor gametes or embryos (7).

The impact that this will have on those being discovered and whether this current reality will change the willingness of individuals to serve as gamete or embryo donors remain to be seen. The collateral effects on genetically linked individuals much removed from the donation process are also unknown but will become clearer over time. Critical to the donation process is the informed consent of donors and recipients regarding the possibility that genetically linked individuals may identify one another, both intentionally and otherwise, at any future date.

Physicians and those who arrange gamete and embryo donation should provide maximum transparency regarding the limits of anonymity to all known stakeholders at the time of the donation, beginning with the change in nomenclature when referring to directed (identified) and nonidentified gamete and embryo donors.

Acknowledgments: This report was developed under the direction of the Practice and Ethics Committees of the American Society for Reproductive Medicine (ASRM) as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice and Ethics Committees and the Board of Directors of the American Society for Reproductive Medicine have approved this report.

This document was reviewed by the ASRM members, and their input was considered in the preparation of the final document. The following members of the ASRM Practice and Ethics Committees participated in the development of this document: Alan Penzias, MD; Kristin Bendikson, MD; Marcella I. Cedars, MD; Tommaso Falcone, MD; Karl Hansen, MD, PhD; Micah Hill, DO; Sangita Jindal, PhD; Suleena Kalra, MD, MSCE; Jennifer Mersereau, MD; Catherine Racowsky, PhD; Richard Reindollar, MD; Chevis N Shannon, DrPH, MPH, MBA; Anne Steiner, MD, MPH; Cigdem Tanrikut, MD; Michael Thomas, MD; Belinda Yauger, MD; Sigal Klipstein, MD; Deborah Anderson; Kavita Shah Arora, MD, MBE; Tolulope Bakare, MD; Katherine Cameron, MD; Susan Crockin, JD; Ruth Farrell, MD; Catherine Hammack–Aviran, MA, JD; Mandy Katz-Jaffe, PhD; Jennifer Kawwass, MD; Edward Martinez, MD; Joshua Morris, MD; Robert Rebar, MD; Eli Reshef, MD; Chevis N Shannon, DrPH, MPH, MBA; Hugh Taylor, MD; Sean Tipton, MA; and Julianne Zweifel, PhD. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. The members of the Committees who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.

REFERENCES

1. Regalado A. 2017 was the year consumer DNA testing blew up. Available at: https://www.technologyreview.com/2018/02/12/145676/2017-was-the-year-consumer-dna-testing-blew-up/. Accessed March 23, 2022.